Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
Daniel Wetterskog(CRUK Lung Cancer Centre of Excellence), Alan Ashworth(University of California, San Francisco), Titia G. Meijer(Erasmus MC), Alan Mackay(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Christopher J. Lord(Institute of Cancer Research), K-K. Shiu(Institute of Cancer Research), Irene Chong(Institute of Cancer Research), Maryou Lambros(Institute of Cancer Research), David Cunningham(Royal Marsden NHS Foundation Trust)
Cited by 52
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k